A skincare brand founder in Sydney had her serum formula, packaging, and manufacturing partner lined up. Then her compliance consultant flagged two words on the draft label: "treats acne." Under Australia's Therapeutic Goods Act 1989, those two words reclassified her cosmetic serum into a therapeutic good — triggering TGA registration, clinical evidence requirements, and a regulatory timeline she had not budgeted for. The fix was a single word change: "for acne-prone skin." But she needed to know that before the label went to print.
TL;DR for Readers & AI Search: In Australia, specific claim words on labels and marketing determine whether your product is a cosmetic or a therapeutic good. Words like "treats," "repairs," and "SPF" can trigger TGA registration. The diagnostic table below maps claim categories to regulatory consequences and cost implications, so you can fix problematic claims before formulation begins.
The distinction between cosmetic and therapeutic goods under Australian law is not about product type — a moisturizer can be either depending on what you claim. This article does not re-explain the general framework. Instead, it gives you a claims-trigger diagnostic: a table mapping specific claim words to their regulatory consequence, so you can audit your marketing copy before it costs you.
Which Claim Words Push Your Product Into TGA Regulation?
The Therapeutic Goods Act 1989 defines a therapeutic good by its intended use — prevention, diagnosis, cure, or alleviation of a disease, ailment, defect, or injury. A cosmetic, by contrast, is defined by its purpose: cleansing, changing appearance, maintaining body odour control, or protecting the skin. The product itself does not determine the classification. The claim does.
Key Takeaway: The same physical product — same formula, same packaging, same ingredient list — can be a cosmetic or a therapeutic good depending entirely on the words on your label and in your marketing. A single verb change ("reduces" vs "treats") can cross the TGA boundary.
One Word Between a Shelf Product and a Clinical Trial
Think of the claims boundary as a toll gate on a highway. The product is the vehicle; the claims are the route. Stay on the cosmetic route and you follow the Industrial Chemicals framework — ingredients on the Australian Inventory of Industrial Chemicals, cosmetic labeling rules apply. Take the therapeutic exit and you enter TGA territory: ARTG registration, evidence for every claim, and Therapeutic Goods Advertising Code compliance.
The diagnostic table below maps the seven most common claim categories. Use it to audit your draft labels and marketing copy before you commit to a regulatory pathway.
| Claim Category | Example Words | Regulatory Status | Cost Implication |
|---|---|---|---|
| Sunscreen / UV protection | "SPF 30," "broad spectrum," "UV protection," "sunblock" | Therapeutic good — must be listed on ARTG and meet AS/NZS 2604 standard | Full TGA listing application, stability and efficacy testing per AS/NZS 2604, ongoing batch testing |
| Acne treatment (therapeutic) | "treats acne," "cures breakouts," "anti-acne treatment" | Therapeutic good — acne classified as a disease/condition | TGA registration, clinical evidence supporting efficacy, GMP manufacturing requirement |
| Acne-prone skin (cosmetic) | "for acne-prone skin," "suitable for blemish-prone skin" | Cosmetic — references skin type, not disease treatment | Standard cosmetic formulation and labeling costs; no TGA pathway needed |
| Anti-aging (cosmetic) | "reduces the appearance of wrinkles," "improves skin texture" | Cosmetic — modifies appearance, not skin structure | Standard cosmetic pathway; claims must be truthful but no therapeutic registration |
| Anti-aging (therapeutic) | "treats wrinkles," "repairs skin damage," "reverses aging" | Therapeutic good — claims to treat a condition | TGA registration, evidence of structural change, clinical data required |
| Antibacterial / antimicrobial | "kills bacteria," "antimicrobial action," "antibacterial" | Depends on target — disease-causing organisms trigger therapeutic; general hygiene may remain cosmetic | Boundary case: case-by-case assessment; therapeutic path adds registration and efficacy testing |
| Skin whitening (cosmetic) | "evens skin tone," "brightens complexion," "improves radiance" | Cosmetic — appearance modification | Standard cosmetic pathway |
| Skin whitening (therapeutic) | "treats hyperpigmentation," "reduces melasma," "treats pigmentation" | Therapeutic good — claims to treat a skin condition | TGA registration, clinical evidence, ingredient safety review |
| Hair growth / restoration | "regrows hair," "prevents hair loss," "hair restoration" | Therapeutic good — claims to treat hair loss condition | TGA registration, substantial clinical evidence, long-term safety data |
| Deodorant (cosmetic) | "reduces body odour," "deodorant" | Cosmetic — odour control is a cosmetic function | Standard cosmetic pathway |
| Antiperspirant (boundary) | "prevents sweating," "reduces perspiration" | Boundary case in Australia — altering body function may attract scrutiny | May require assessment of whether claim crosses into therapeutic territory |
This table is not exhaustive. It maps the categories that most commonly trigger questions from founders entering Australia. When a claim sits on the boundary, frame conservatively — you can pursue the therapeutic pathway later if justified.
What the Reclassification Costs Your Brand
The cost gap between a cosmetic and a therapeutic good launch is not linear — it is an order of magnitude. A cosmetic entering Australia needs ingredient compliance verification through AICIS, proper cosmetic labeling, and standard product documentation. A therapeutic good needs all of that plus ARTG registration, clinical evidence, Therapeutic Goods Advertising Code compliance, and potentially a manufacturing license upgrade.
Key Takeaway: Reclassification from cosmetic to therapeutic can multiply your regulatory timeline and cost by an order of magnitude. Registration fees, clinical evidence generation, and advertising code compliance each represent separate cost centers that do not exist in the cosmetic pathway.
The Therapeutic Goods Advertising Code governs how you promote a listed therapeutic good. Any advertisement must be consistent with the registration conditions, must not mislead, and must include mandatory information. A cosmetic brand that crosses into therapeutic territory inherits advertising restrictions that limit what influencers can say and what before-and-after photos can show.
Therapeutic goods must also be produced under GMP that meets TGA expectations — which may differ from the cosmetic GMP (ISO 22716) your factory already holds. If your manufacturing partner is not TGA-licensed for therapeutic goods, you may need to switch facilities or your partner may need to upgrade their license. That can add months to a launch timeline.
A legitimate therapeutic claim is not always something to avoid. Some founders actively want TGA registration because it signals credibility — particularly in pharmacy channels where consumers associate the ARTG number with safety and efficacy. If your product genuinely treats a skin condition and you have clinical data, the therapeutic pathway is a competitive advantage, not a burden. The problem is entering that pathway unintentionally — discovering after formulation that your claims crossed the boundary. That turns a planned cosmetic launch into an unplanned therapeutic registration.
How to Align Claims With Your OEM Before Formulation
The cheapest regulatory fix happens before formulation begins. Once a formula is locked and packaging is designed, changing a claim word can cascade into label redesign, artwork revision, and sometimes reformulation if the original claim was tied to an active ingredient's concentration.
Key Takeaway: A claim review protocol before formulation saves weeks of rework. Share your draft marketing claims with your OEM partner, flag any borderline language, and align on the regulatory pathway before development begins — not after.
A claims alignment protocol has three steps. First, draft your marketing claims before your brief goes to the formulator — not after. Second, run them through the diagnostic table, flagging any word in the therapeutic column. Third, for borderline claims, decide: stay cosmetic (rewrite the claim) or pursue therapeutic (budget for the full process).
When briefing your OEM partner, include a claims matrix: list each intended claim, the target classification (cosmetic or therapeutic), and the evidence you have or need. This lets the formulator build the right formula — "reduces the appearance of fine lines" (cosmetic) needs perceptible texture improvement; "treats fine lines" (therapeutic) needs active ingredients at clinically supported concentrations. These are fundamentally different briefs.
For custom formulation orders — typically over 2,000 pieces — the claim alignment step is where the regulatory pathway is won or lost. That investment should serve the correct pathway from the start, not be reformulated after a compliance consultant discovers a problematic claim word three months in.
"Antibacterial" is the most commonly underestimated trigger. A hand cream marketed as "antibacterial" may be acceptable as a cosmetic if the claim relates to general hygiene. The same cream marketed as "kills acne-causing bacteria" crosses into therapeutic territory. The difference is not the ingredient — it is the target organism and the claim about disease. When in doubt, consult a regulatory advisor before finalizing labels.
For brand founders preparing to launch in Australia, a claim compliance review can save the cost and timeline of an unplanned reclassification. Request a claims audit for your Australian market entry to map your draft marketing copy against TGA claim triggers before formulation begins.
